Press Release

                     DIALYSIS CORPORATION OF AMERICA
             ANNOUNCES EXTENSION OF WARRANT EXERCISE PERIOD

Lemoyne, Pennsylvania, March 21, 2000 - Dialysis Corporation of America
(Nasdaq SmallCap Market-DCAI) announces its third extension of the
exercise period of its outstanding publicly traded redeemable common stock
purchase warrants ("Warrants") from March 31, 2000 to June 30, 2000.  The
Company believes it appropriate to the marketplace and fair to the Warrant-
holders to allow them the opportunity to relate to the Company's proposed
reorganization, which includes the sale of its assets to a wholly-owned
subsidiary of its parent, Medicore, Inc., which currently holds a 65%
interest in the Company, and immediately thereafter a merger with MainStreet
IPO.com Inc. ("MainStreet").  MainStreet filed a registration statement on
Form S-4 with respect to the proposed transactions in which the Company
included its proxy statement.  That document is in preliminary form, and
recently received extensive comments from the staff of the Securities and
Exchange Commission.

     We feel it would be fair to the marketplace and to security holders to
continue to evaluate our Company and have the additional time to consider the
overall situation and have the opportunity to determine whether they wish to
exercise their DCA Warrants.

     To date, the Company has been advised that approximately 141,000
Warrants have been exercised, leaving a balance of 2,159,000 Warrants that
continue to trade on the Nasdaq SmallCap Market (symbol "DCAIW"), and will
be eligible for exercise if the warrantholders so desire.  The exercise price
is $4.50 per share for one share of the Company's common stock.  The closing
prices of the common stock and the Warrants on Monday, March 20, 2000 as
reported by Nasdaq were $4.63 and $.41, respectively.

    This release contains forward-looking statements that are subject to
risks and uncertainties, including but not limited to the volatility of the
prices of the common stock and Warrants, the possible inability to satisfy
the comments and concerns of the staff of the Commission relating to the
proposed merger and sale of assets transactions and proposed operations of
MainStreet, or if so satisfied, that such transactions may not be submitted
to or approved by the Company's shareholders, future business events, general
economic conditions, regulation of MainStreet's proposed operations,
regulation of dialysis operations, government rate modification for Medicare
reimbursement, the highly competitive environment in the operation and
acquisition of dialysis centers, as well as the proposed Internet operations
for direct public offerings as proposed by MainStreet, the absence of
operations and revenues of MainStreet, and other risks detailed from time to
time in the Company's and MainStreet's filings with the Commission.

CONTACT:  For more information, contact Thomas K. Langbein, CEO, Dialysis
Corporation of America, 777 Terrace Avenue, Hasbrouck Heights, New Jersey
07604.  Telephone No. (201) 288-8222.